EUCTR2018-000635-27-AT进行中（未招募）1 期
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.)0 个研究点目标入组 103 人开始时间: 2018年9月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 103
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Have histologically or cytologically confirmed stage IIIB (locally advanced or recurrent and not a participant for curative therapy) or stage IV non–small-cell lung cancer (NSCLC).
- •2. Must meet both of the following 2 criteria:
- •a. Have documentation of anaplastic lymphoma kinase (ALK) rearrangement by a positive result from any laboratory test® approved by the food and drug administration (FDA) or Have documented ALK rearrangement by a different test (non–FDA-approved local lab tests) and have provided tumor sample to the central laboratory. (Note: Central laboratory ALK rearrangement testing results are not required to be obtained before randomization.)
- •b. Had been on any one of the ALK tyrosine kinase inhibitor (TKIs) (alectinib, ceritinib, crizotinib) for at least 12 weeks before progression.
- •3. Had progressive disease (PD) while on alectinib or ceritinib
- •4. Had alectinib or ceritinib as the most recent ALK inhibitor therapy.
- •5. Have at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) version 1.1 as assessed by the investigator.
- •6. Had recovered from toxicities related to prior anticancer therapy to national cancer institute common terminology criteria for adverse events (NCI CTCAE), version 4.03, Grade =1. (Note: Treatment-related alopecia or peripheral neuropathy that are Grade >1 are allowed if deemed irreversible.) and have adequate major organ functions.
- •7. Have a life expectancy of =3 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 83
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Had received any prior ALK-targeted TKI other than crizotinib, alectinib, or ceritinib.
- •2. Had received both alectinib and ceritinib.
- •3. Had previously received more than 3 regimens of systemic anticancer therapy for locally advanced or metastatic disease.
- •4. Had symptomatic brain metastasis (parenchymal or leptomeningeal). Participants with asymptomatic brain metastasis or who have stable symptoms that did not require an increased dose of corticosteroids to control symptoms in the past 7 days before the first dose of brigatinib may be enrolled.
- •5. Had current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with leptomeningeal disease and without cord compression are allowed.
- •6. Had a cerebrovascular accident or transient ischemic attack within 6 months before first dose of brigatinib.
- •7. Had an ongoing or active infection, including, but not limited to, the requirement for intravenous antibiotics.
- •8. Had malabsorption syndrome or other gastrointestinal (GI) illness that could affect oral absorption of brigatinib.
研究者
相似试验
已完成
2 期
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non*Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib10038666lung cancernon-small cell lung cancerNL-OMON49812ARIAD Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited4
进行中（未招募）
1 期
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibAnaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000635-27-DEARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.)103
已完成
2 期
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib ( ALTA-2 )ALK-positive Advanced NSCLCJPRN-jRCT2080224831Takeda Pharmaceutical Company Limited103
进行中（未招募）
1 期
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+),Advanced Non Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibAnaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non¿Small-Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000635-27-ITARIAD PHARMACEUTICALS, INC.103
进行中（未招募）
1 期
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibAnaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC)MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000635-27-NLARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.)103